

PROGRAM

Monday, April 11

8:00~8:10 ***Opening remarks***

Conference Chair: Ryo Nishikawa (Japan)

8:10~9:07 ***Session 1 Molecular Biology***

Moderator: Erwin Van Meir (USA)

O-1 Genetically Engineered GBM Mouse Models: *in vivo* Expression of Mutated IDH1 (R132H) Gene Using the Sleeping Beauty Transposase System
Maria G. Castro(USA)

O-2 Pre-Clinical Efficacy of EZH2 Inhibition in the Genetically-Engineered *IDH1* Wild-Type Proneural GBM Mice
Fumiharu Ohka(Japan)

O-3 Mutant IDH Expression Drives Hert Reactivation as Part of the Cellular Transformation Process
Russell Pieper(USA)

O-4 Therapeutic Vulnerability of IDH1 Mutant Gliomas to NAD+ Depletion
Daniel P. Cahill(USA)

O-5 Identifying Novel Vulnerabilities in Oxidative Stress Pathways in IDH1 Mutant Glioma
Simone P. Niclou(Luxembourg)

O-6 Mutant IDH1 Suppresses Local and Systemic Thrombosis in Glioma Patients
Craig Horbinski(USA)

O-7 ATRX Reduction Promotes Chemoresistance and Xenograft Growth in Glioblastoma
Charles Eberhart(USA)

O-8 ATRX Deficiency Promotes Invasive Behavior in Glioma Cells of Origin by Dysregulating Chromatin Accessibility and Modulating Gene Expression
Jason T Huse(USA)

O-9 Mitochondrial Metabolism Suppression by PGK1
Zhimin Lu(USA)

O-10 Alternate Activation of the Pentose Phosphate Pathway and Glycolysis Are Intrinsic to the Proliferative/Migratory Glioma Phenotype - Independent from Hypoxia
Katrín Lamszus(Germany)

O-11 Inhibition of Hexokinase 2 Through Tumor Glycolysis Inhibitors Identified Through a Drug Screen Inhibits Glioblastoma Growth *in vitro* and *in vivo*
Gelareh Zadeh(Canada)

O-12 Non-Metabolic Function of Phosphofructokinase-1 in Glioblastoma Maintenance
Petra Hamerlik(Danmark)

O-13 Control of Glucose Uptake in Glioblastoma Cells
Lorenzo Magrassi(Italy)

O-14 Glucose-Dependent Mechanism of Targeted Cancer Therapy Resistance
Kenta Masui(Japan)

O-15 Coexpression of Fatty Acid Synthase (FASN) and Carnitine Palmitoyltransferase 1C (CPT1C) in Human Gliomas and Glioma Stem Cell Xenografts
Tatsuya Abe(Japan)

O-16 SCAP Integrates Oncogenic Signaling and Metabolism for Glioblastoma Growth
Deliang Guo(USA)

9:10~9:52 **Session 2 Molecular Biology-2**

Moderator: Shi-Yuan Cheng (USA)

★15min (Presentation 13min + QA 2min)

★ O-17 Redefining the Cellular Architecture of Human Gliomas Through Large-Scale Single-Cell Analyses
Mario L. Suva(USA)

O-18 Drosophila Brat and Human Ortholog TRIM3 Regulate Asymmetric Cell Division in Brain Tumor Stem Cells Through Notch Signaling
Daniel J. Brat(USA)

O-19 Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres
Manabu Natsumeda(Japan)

O-20 Glioma Stemness as a Moving Therapeutic Target
Ichiro Nakano(USA)

O-21 Exploiting Exosomes from Human Bone Marrow Mesenchymal Stem Cells to Deliver Therapeutic microRNAs to Gliomas
Frederick F. Lang(USA)

O-22 Human Fat-Derived Mesenchymal Stem Cells Bioengineered to Secrete BMP4 Are Non-Oncogenic, Suppress Glioma, and Prolong Survival
Sara Ganaha(USA)

9:52~10:15 **Coffee Break**

10:15~11:30 **Session 3 Molecular Biology-3**

Moderator: Ichiro Nakano (USA)

O-23 N-Cadherin Upregulation Mediates Adaptive Radioresistance in Glioma Stem Cells
Satoru Osuka(USA)

O-24 Combined Targeted Inhibition of STAT3 and the Epigenetic Regulator LSD1 Sensitize Mesenchymal GBM Stem-Like Cells to Radiation
Howard Colman(USA)

O-25 TIE2 Mediates DNA Repair in Brain Tumor Stem Cells Via Histone Phosphorylation and ABL Recruiting
Juan Fueyo(USA)

O-26 Targeting the Tumor Microenvironment in GBM
Karl H. Plate(Germany)

O-27 c-Met/β1 Integrin: A Receptor Complex Driving Invasive Resistance to Anti-Angiogenic Therapy
Manish K. Aghi(USA)

O-28 Cross-Talk of the Vascular Endothelial Growth Factor and Transforming Growth Factor-Beta Pathways in Glioblastoma
Michael Weller(Switzerland)

O-29 SHP-2-Upregulated ZEB1 Is Important for Pdgfralpha-Driven Glioma Epithelial-Mesenchymal Transition and Invasion
Haizhong Feng(CHINA)

O-30 IL-33 Orchestrates the Brain Tumor Microenvironment to Promote Glioma Progression and Therapeutic Resistance
Donna L. Senger(Canada)

O-31 The Role of Stress Granules in Astrocytoma Cell Signaling
James T. Rutka(Canada)

O-32 Tenascin C Is Developmentally Regulated by the PAX6 and DLX2 Homeobox Genes During Forebrain Development – Implications for Glioma Invasion
David D. Eisenstat(Canada)

O-33 NKG2D-Dependent Immune Surveillance Contributes to Anti-Tumor Effects of Chemotherapy and Radiotherapy Against Glioblastoma
Patrick Roth(Switzerland)

O-34 EEF1A1-PLCG1 Axis Is a Novel Therapeutic Target Against Gliomas with Acquired Temozolomide Resistance or Adaptation
Arata Tomiyama(Japan)

O-35 EGFR Inhibitor Resistance Mechanisms in GBM
Joanna J. Phillips(USA)

O-36 Up-Regulation of MSK1/β-Catenin Signaling Leads to Adaptive Resistance to PI3K/mTOR Inhibition in Human Glioblastoma
W.K. Alfred Yung(USA)

O-37 ERK Inhibitors Show Efficacy Against BRAF-Mutant Gliomas
Theodore Nicolaides(USA)

O-38 PID1, a Brain Tumor Growth Inhibitor, Is a Novel Interacting Partner and Regulator of Critical Receptor Kinase Signaling
Anat Erdreich-Epstein(USA)

O-39 Tyrosine Phosphorylation of Nuclear PTEN Promotes Therapeutic Resistance Through Enhanced DNA Damage Repair
Frank Furnari(USA)

O-40 HuR Multimerization Is Oncogenic in Glioma
Louis Nabors(USA)

O-41 Ionizing Radiation Induces BRCA1-Nuclear Export and Glioma Synthetic Lethality of PARP1 Inhibition in a P53-Dependent Manner
Fen Xia(USA)

O-42 A Regulatory Circuit of miR-125b/miR-20b and Wnt Signaling Controls GBM Phenotypes Through FZD6-Mediated Pathways
Shi-Yuan Cheng(USA)

O-43 mRNA-Seq of Tumefaction-Educated Platelets (TEPs) as a Tool for Blood-Based Diagnosis and Monitoring of Cns Lesions
Pieter Wesseling(Netherlands)

11:33~12:15 **Session 4 Other Biological Issues**

Moderator: Joseph Costello (USA)

O-44 A Glioblastoma Methylation Assay (GaMA) Developed from Genomic Analysis of Glioma Spheroid Cultures (GSCs) Predicts Response to Radiation Therapy
Erik P. Sulman(USA)

O-45 The Prognostic and Predictive Value of an Explant Assay of Gliomas in Response to Temozolomide
David R. Macdonald(Canada)

O-46 Gene-Drug Association Screening-Guided Precision Neuro-Oncology: Implication of Spatiotemporal Heterogeneity in Glioblastoma Genome
Do-Hyun Nam(Korea)

O-47 Precision Medicine in Recurrent Glioblastoma: A Feasibility Trial Conducted by the Ivy Foundation Early Phase Clinical Trials Consortium
Michael D. Prados(USA)

O-48 Personalizing the Treatment for Glioblastoma Patients
Kerrie L. McDonald(Australia)

O-49 Identification of Cytotoxic Chemical HUP1 Against the Temozolomide-Resistant Glioblastoma-Initiating Cells by a High-Throughput Drug Screening
Toru Kondo(Japan)

O-50 Biomarkers of Glioblastoma Identified by Quantitative Proteomics with Swath Mass Spectrometry
Mitsutoshi Nakada(Japan)

- O-51** Molecular-Guided Neoadjuvant Chemotherapy for Gliomas
Hikaru Sasaki(Japan)
- O-52** Circulating Tumor Cells in Glioblastoma
Manfred Westphal(Germany)
- O-53** Non-Invasive Assessment of Glioblastoma Biology Using Circulating Tumor DNA
Colin Watts(UK)
- O-54** Ultra-Early Detection of Gliomas with Serum Autoantibodies for Specific Glioma Antigens
Yasuo Iwadate(Japan)
- O-55** Detection of D-2-Hydroxyglutarate in the Cerebro-Spinal Fluid of Glioma Patients with Mutant *IDH1* Genes
Erwin Van Meir(USA)

12:30~13:30 **Lunchtime Seminar 1** (Sponsor: MSD K.K.)

Moderator: Kazuhiko Mishima (Japan)

- LS-1** Receptor Tyrosine Kinase Signaling Underlies Tumor Growth Through Epigenome and Transcription Factor Network Remodeling
Webster Cavenee(USA)

13:45~15:12 **Session 5 Immunology** (Sponsor: Toray Industries, Inc.)

Moderator: Hideho Okada (USA)

★15min (Presentation 13min + QA 2min)

- ★ **S1-1** Bone Marrow T Cell Sequestration with GBM
Peter E. Fecci(USA)
- ★ **S1-2** Immunological Changes During Tumor Progression from Primary to Recurrent Glioblastoma
Christel C. Herold-Mende(Germany)
- S1-3** Novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27M Mutation
Hideho Okada(USA)
- S1-4** Third Generation CARs with Reduced IL-2 Signaling Overcome Treg Suppression and Mount a Therapeutic Response Against Established Solid Tumors
Gary Archer(USA)
- S1-5** The CAR2Brain-Study: A Phase I Study of Local Therapy with ErbB2/Her2-Targeted NK Cells for Recurrent Glioblastoma
Joachim P. Steinbach(Germany)
- S1-6** Vaccination with Dendritic Cells Loaded with Cytomegalovirus Antigen in Patients with GBM and Associations with Overall Survival
John H. Sampson(USA)
- S1-7** Co-Stimulatory Molecules, OX40 and CD40, Augment the Efficacy of Tumor Lysate-Based Vaccines Against Malignant Gliomas
Ryuta Saito(Japan)
- S1-8** Phase I Clinical Trial of IDH1 Vaccine in Recurrent Low Grade Gliomas
Gordana Vlahovic(USA)
- S1-9** WT1 Peptide Vaccination for Glioblastomas; Survivals, Biomarkers and Response Assessments
Naoya Hashimoto(Japan)
- S1-10** Novel WT1 Peptide Vaccination for Newly Diagnosed Malignant Gliomas
Tetsuya Ueba(Japan)
- S1-11** Autologous Formalin Fixed Tumor Vaccine for Patients with Newly-Diagnosed Glioblastoma; From Concept to Double Blind Phase IIb/III trial
Yoshihiro Muragaki(Japan)

S1-12 Synergistic Effects of Regulatory and Memory T Cell Modulation in Dendritic Cell-Based Immunotherapy: Impact of mTOR and NFkB Pathway
Yohei Mineharu(Japan)

S1-13 Therapeutic Doses of Temozolomide Inhibit IL-10 Production by Dendritic Cells and Enhance the CTL Response
Akio Asai(Japan)

S1-14 Engineering the Brain Immune System to Recognize and Eliminate Brain Tumors: Ad-Fit3L and Ad-TK Reconstitute Brain Immunity to Recognize Neo-Antigens -Initial Reports on a Phase I Clinical Trial
Pedro R. Lowenstein(USA)

S1-15 A Phase I Study of a Personalized Neoantigen Cancer Vaccine with Radiotherapy Among MGMT Unmethylated, Newly Diagnosed Glioblastoma Patients
David Reardon(USA)

S1-16 Glioma Microenvironment-Derived CCL2 Recruits Regulatory T Cells and Myeloid-Derived Suppressor Cells
Maciej S. Lesniak(USA)

S1-17 Phase I Study to Determine the MTD of a Recombinant Immunotoxin Targeting Wildtype EGFR and Mutant EGFRvIII in Recurrent Glioblastoma Patients
Vidyalakshmi Chandramohan(USA)

S1-18 The Effect of Ttfields on T Cells Immune Functionality
Zvi Ram(Israel)

S1-19 Germline Mutations Predict Response of Recurrent Glioblastoma to Immune Checkpoint Inhibition
Uri Tabori(Canada)

15:12~15:30 **Coffee Break**

15:30~16:30 **Special Lecture** (Sponsor: Eisai Co., Ltd.)

Moderator: Motoo Nagane (Japan)

SL-1 Targeting Essential Growth Drivers in Cancer
Hiroyuki Mano(Japan)

16:45~17:48 **Session 6 Viral and Genetherapies**

Moderator: Tomoki Todo (Japan)

★15min (Presentation 13min + QA 2min)

★ **O-56** Intratumoral Administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Against Recurrent WHO Grade IV Malignant Glioma (MG)
Annick Desjardins(USA)

O-57 Oncolytic Poliovirus Immunotherapy of Malignant Glioma
Matthias Gromeier(USA)

O-58 Clinical Development of Oncolytic HSV-1 G47delta for Glioblastoma
Tomoki Todo(Japan)

O-59 Third Generation Oncolytic HSV-1 (G47delta) Is Efficacious Against Glioblastoma-Derived Cancer Initiating Cells
Yasushi Ino(Japan)

O-60 Toxicity Study of Lentiviral HSV-Tk Mediated Suicide Gene Therapy in the Rat Brain
Hrvoje Miletic(Norway)

O-61 Histone Deacetylase 6 Inhibition Enhances Oncolytic Viral Replication in Glioma
E. Antonio Chiocca(USA)

O-62 Oncolytic Viral Therapy for Brain Tumors
Balveen Kaur(USA)

O-63 Cell-Based Oncolytic Virotherapy of Experimental Gliomas
Ghazaleh Tabatabai(Germany)

O-64 Combination Viro-Immunotherapy with Checkpoint Inhibition to Treat Glioma, Based on Location-Specific Tumor Profiling
Brian Patrick O'Neill(USA)

O-65 Combination of Oncolytic Adenoviruses and Immune Checkpoint Targeting
Juan Fueyo(USA)

O-66 A Super Gene Expression System Enhances the Antitumor Effects of Adenovirus-Mediated REIC/Dkk-3 Gene Therapy
Kazuhiko Kurozumi(Japan)

O-67 Enhanced Efficacy of Prodrug Activator Gene Therapy with a Retroviral Replicating Vector (Toca 511) Combined with Radiation
Masamichi Takahashi(Japan)

O-68 Human iPSC for Cell-Based Gene Therapy of Gliomas
Isabelle M. Germano(USA)

O-69 Towards Clinical Development of an Autologous Stem-Cell Based Glioma Therapy Using iPSC-NSC Derivation Methods
Nils Ole Schmidt(Germany)

17:48~18:06 **Session 7**

Moderator: **Kazuhiko Mishima (Japan)**

Pathology

O-70 Dual Color MGMT/CD45-HAM56 for Corrected Nuclear Counts in Glioblastoma
Roger E. McLendon(USA)

Other Clinical Issues

O-71 Multi-Centre Phase I Trial of the Proteasome Inhibitor Marizomib with Bevacizumab in Patients with Progressive Glioblastoma (GBM)
Warren P. Mason(Canada)

Pediatric-2

O-72 High Diagnostic Value of Placental Alkaline Phosphatase Levels (PLAP) : A New Marker for Intracranial Germ Cell Tumors
Yasuo Aihara(Japan)

Radiation Oncology/Imaging

O-73 Creation of a Dual-Labeled Cancer-Targeting Alkylphosphocholine Analog for Dual Modality Quantitative PET and Intraoperative Tumor Visualization
John S. Kuo(USA)

Surgery, etc.

O-74 Sonodynamic Therapy Combined with a Photosensitizer, 5-Aminolevulinic Acid for Malignant Gliomas
Takanori Ohnishi(Japan)

Tuesday, April 12

8:00~9:09 **Session 8 Pediatric**

Moderator: **Nada Jabado (Canada)**

★15min (Presentation 13min + QA 2min)

★ **O-75** Metastatic Dissemination of Medulloblastoma Is Through the Blood, and Is Mediated by CCL2
Michael D. Taylor(Canada)

O-76 The Medulloblastoma Enhancer Landscape Reveals Subgroup-Specific Cellular Origins
Paul A. Northcott(USA)

O-77 Convergence of Bmi1 and Chd7 in the Pathogenesis of Medulloblastoma
Silvia Marino(UK)

O-78 Integrative Clustering Reveals Distinct Biological Subtypes Within Medulloblastoma Subgroups
Vijay Ramaswamy(Canada)

O-79 BAI1 Silencing Promotes Medulloblastoma Formation Through a P53 Dependent Mechanism
Dan Zhu(USA)

O-80 Clinical Significance of PD-L1 and CD8 Expression in Human Medulloblastoma
Yoshiki Arakawa(Japan)

O-81 A Phase I Trial of P28, a Non-HDM2 Mediated Peptide Inhibitor of P53 Ubiquitination for Pediatric Patients Recurrent CNS Tumors
Stewart Goldman(USA)

O-82 Disruption of GABA Metabolism in Medulloblastoma
Josh Neman(USA)

O-83 Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma
Kenneth Cohen(USA)

O-84 Four New Brain Tumor Entities Emerge From Molecular Classification of CNS PNETs
Marcel Kool(Germany)

O-85 C11orf95-RELA Fusion Alone is Sufficient to Form Human Supratentorial Ependymoma-Like Tumor in Mice
Tatsuya Ozawa(USA)

O-86 Outcome of Young Children with Supratentorial Ependymoma Treated with Radical Surgical Resection and Intensive Chemotherapy: The Head Start I-III Trials, 1991-2009
Jonathan L. Finlay(USA)

O-87 Clinicopathological Features of Atypical Teratoid/Rhabdoid Tumor-Like Embryonal Tumors with Retained INI1 and BRG1 Expression
Junko R. Hirato(Japan)

O-88 Heterogeneity in SWI/SNF Complex Components in Atypical Teratoid Rhabdoid Tumors
Alexander R. Judkins(USA)

O-89 Atypical Teratoid/Rhabdoid Tumor (AT/RT) Arising from Ependymoma: A Type of Secondary AT/RT
Sumihito Nobusawa(Japan)

O-90 Establishment of a Nationwide Molecular Diagnostic Network for Pediatric Malignant Brain Tumors in Japan
Yonehiro Kanemura(Japan)

9:12~10:24 **Session 9 Pediatric-2**

Moderator: **Torsten Pietsch (Germany)**

★15min (Presentation 13min + QA 2min)

★ O-91 Cellular Origin of Central Nervous System Germ Cell Tumors
Koichi Ichimura(Japan)

O-92 Expression Profiling of Intracranial Germ Cell Tumors Reveals Upregulation of RAS Through mRNA-microRNA Signaling Pathway
Ching C. Lau(USA)

O-93 Dose-Reduced Radiotherapy with Platinum-Based Chemotherapy Has Improved Quality of Life in the Long-Term Survivors with Germinoma
Kazuhiko Sugiyama(Japan)

O-94 MicroRNA 372-373 in Cerebrospinal Fluid Is Potential Tumor-Derived Biomarkers for CNS Germ Cell Tumors
Keita Terashima(Japan)

O-95 Long-Term Survival with Multimodal Therapy; Surgery, Carboplatin Based Chemotherapy Followed by Radiotherapy in Patients with Primary Intracranial Germ Cell Tumors
Kazuya Motomura(Japan)

O-96 Management of Intracranial Germ Cell Tumors – International Consensus and Differences
Ute Bartels(Canada)

O-97 Pediatric Low-Grade Glioma Molecular Stratification and Long Term Implications
Cynthia E. Hawkins(Canada)

O-98 Type II Raf Inhibitors as Targeted Therapeutics for Pediatric Low-Grade Astrocytoma
Mark W. Kieran(USA)

O-99 The Prognostic Factors of Pilocytic Astrocytoma in Children: A Retrospective Review of 16 Cases
Kentaro Chiba(Japan)

O-100 Functional Diversity and Co-Operativity Between Subclonal Populations of Paediatric Glioblastoma and Diffuse Intrinsic Pontine Glioma Cells
Chris Jones(UK)

O-101 Functional Dissection of the H3.3K27M Mutation
Oren Becher(USA)

O-102 Histopathological WHO Grading and H3.3K27 Mutational Status Represent Independent Prognostic Markers in Pediatric High Grade Gliomas
Torsten Pietsch(Germany)

O-103 Spatial and Temporal Homogeneity of Driver Mutations in Diffuse Intrinsic Pontine Glioma
Nada Jabado(Canada)

O-104 Targeting Enzymatic Modifiers of Histone H3 K27 for Treating DIPG
Charles David James(USA)

O-105 PNO-003: Precision Medicine Trial for Children with Diffuse Intrinsic Pontine Glioma
Sabine Mueller(USA)

O-106 Microenvironment and Tumor Cell Expansion in Diffuse Intrinsic Pontine Glioma
Javad Nazarian(USA)

O-107 Home-Based Palliative Care for Children with Recurrent and/or Refractory Cen Tral Nervous System Tumor
Takaaki Yanagisawa(Japan)

10:24~10:50 **Coffee Break**

10:50~12:29 Session 10 Molecular Genetics (Sponsor: Nobelpharma Co., Ltd.)

Moderator: Koichi Ichimura (Japan)

★15min (Presentation 13min + QA 2min)

★ S2-1 Novel Brain Tumor Subtypes Identified by Genome-Wide Methylome Profiling
David T.W. Jones(Germany)

★ S2-2 Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
Roeland GW Verhaak(USA)

S2-3 Genome-Wide Methylation Analysis Identifies Genomic DNA Demethylation During Malignant Progression of Gliomas
Akitake Mukasa(Japan)

S2-4 Genome and Epigenome Perspectives of Human Brain Tumor Evolution
Joe Costello(USA)

S2-5 De Novo Transcriptome Assembly Finds Novel Glioblastoma Subtype-Specific Transcripts
Bernhard Radlwimmer(Germany)

S2-6 High-Throughput Screening (HTS) of Glioma Stem-Like Cells (GSCs) Identifies Genomic Correlates of Therapeutic Response to Targeted Therapy
John de Groot(USA)

S2-7 Genomic Tests Accurately Classify Gliomas into Five Molecular Groups and Provide Additional Information on Acquired Alterations and Clinical Outcome
Robert B. Jenkins(USA)

S2-8 ATRX and TERT Assays Provide Complementary Information in Adults with IDH-Mutated Glioma
Kyle M. Walsh(USA)

S2-9 Molecular Classification Based on IDH and TERT Identified Four Clinically Distinct Subclasses: A Study of Glioma Molecular Classification Consortium
Hideyuki Arita(Japan)

S2-10 Mutations in IDH1, IDH2, and in the TERT Promoter Define Clinically Distinct Subgroups of Adult Malignant Gliomas
Hai Yan(USA)

S2-11 Preliminary Results of Phase I Study of AG-120, an Inhibitor of the IDH1 Mutant Protein, in Patients with IDH1-Mutant Solid Tumors, Including Gliomas
Patrick Y. Wen(USA)

S2-12 Detection of IDH1 Mutations in vivo by Magnetic Resonance Spectroscopy of Glutamate and 2-Hydroxyglutarate in Human Brain Gliomas
Kazuhiro Tanaka(Japan)

S2-13 NGS-Based MSK-IMPACT Analysis Reveals Specific Genetic Alterations in Recurrent Glioblastoma
Shinya Tanaka(Japan)

S2-14 Genetic Biomarkers to Predict Prognosis and Kinetics of Clonal Evolution by Mathematical Computational Modeling in Low-grad Glioma
Atsushi Natsume(Japan)

S2-15 Malignant Transformation in Oligodendrogloma with 1p19q LOH
Hideo Nakamura(Japan)

S2-16 Treatment Strategy for Grade II-III Gliomas Could Be Determined by IDH and TP53 Status
Yuichi Hirose(Japan)

S2-17 Genetic and Histological Stability of 1p/19q Co-Deleted Gliomas at Recurrence
Keisuke Ueki(Japan)

S2-18 Co-Polysomy of Chromosomes 1 and 19 Predict Early Recurrence Among Non-1p/19q-Deleted Low-Grade Gliomas
Rachel Grossman(USA)

S2-19 HDAC7 as a Possible Therapeutic Target for Mesenchymal Glioblastoma
Koji Yoshimoto(Japan)

S2-20 G Protein-Coupled Receptor 158: A Potential Prognostic Biomarker in Gliomas
Sebastian Brandner(UK)

S2-21 Statistical Considerations for Developing Classification Models in Glioma
Annette M. Molinaro(USA)

S2-22 Evolution of Molecular Drivers in Glioblastomas During Temozolomide Treatment
Tracy Batchelor(USA)

S2-23 Intraoperative Detection of IDH1 Mutations in Diffuse Gliomas
Takashi Komori(Japan)

12:35~12:56 ***Session 11 Pathology***

Moderator: **Takashi Komori (Japan)**

O-108 Detection of P53 Mutations in Proliferating Vascular Cells in Glioblastoma Multiforme
Hideo Takeshima(Japan)

O-109 Practical Utility of Nestin and Olig2 as Immunohistochemical Markers for Gliomas
Hideaki Yokoo(Japan)

O-110 Expression of Multidrug Resistant Genes in the Human Glioblastomas
Takashi Tamiya(Japan)

O-111 Clinical and Pathological Characteristics of Adult Diffuse Brainstem Glioma
Shota Tanaka(Japan)

O-112 Microtube Networks Constitute a Major Resistance Factor in Gliomas
Wolfgang Wick(Germany)

O-113 Tumor-Associated Macrophages and Microvascular Proliferation in Glioblastoma
Atsushi Sasaki(Japan)

O-114 M2a-type Macrophages in Glioblastoma Are Characterized by Up-Regulation of ALDH1A2
Waldemar Debinski(USA)

13:00~14:00 ***Lunchtime Seminar 2*** (Sponsor: Chugai Pharmaceutical Co., Ltd.)

Moderator: **Keisuke Ueki (Japan)**

LS-2 The New WHO Classification of Brain Tumors
Arie Perry(USA)

Wednesday, April 13

8:00~8:27 **Session 12 Radiation Oncology/Imaging**

Moderator: Susan Chang (USA)

O-115 Magnetic Resonance Analysis of Malignant Transformation in Recurrent Glioma
Susan M. Chang(USA)

O-116 Magnetic Resonance Spectroscopy Detection of High Lipid Levels in Intraaxial Tumors Without Central Necrosis: A Characteristic of Malignant Lymphoma
Kaoru Kurisu(Japan)

O-117 Diagnostic Possibility of Positron Emission Tomography Using [18F]Fluciclovine to Diagnose and to Delineate Gliomas
Toshihiko Wakabayashi(Japan)

O-118 A Prospective Multicenter Single-Arm Clinical Trial of Bevacizumab for Patients with Surgically Untreatable Symptomatic Brain Radiation Necrosis
Shin-ichi Miyatake(Japan)

O-119 A Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab in the Treatment of Recurrent Malignant Glioma
Jennifer L. Clarke(USA)

O-120 Hypo-Fractionated IMRT with TMZ for GBMs -Tailor-Made Setting of Treatment Doses Owing to MGMT-Methylation Status-
Toshihiko Iuchi(Japan)

O-121 Gamma Knife Radiosurgery for Brain Metastases from Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC) : Report of a Japanese Multi-Institutional Co-Operative Study (JLGK 1401 Study)
Takuya Kawabe(Japan)

8:30~9:30 **Special Seminar** (Sponsor: Southern Tohoku General Hospital)

Moderator: Yoko Nakasu (Japan)

ES1-1 Proton Beam Radiotherapy for Intracranial Tumors
Yasuhiro Kikuchi(Japan)

ES1-2 BNCT for the Treatment of Malignant Brain Tumors in Comparison with Other Particle Radiation
Shin-ichi Miyatake(Japan)

9:40~10:00 **Coffee Break**

10:00~10:51 **Session 13 Other Tumors**

Moderator: Kazuhiko Mishima (Japan)

O-122 Genomic Characterization of Primary Central Nervous System Lymphoma
Motoo Nagane(Japan)

O-123 Reduced Neurotoxicity with Methotrexate-Based Multiagent Chemotherapy (M-CHOP) and Deferred Radiotherapy for Primary Central Nervous System Lymphoma
Tomotsugu Ichikawa(Japan)

O-124 Prognostic Impact of Completion of Initial High-Dose Methotrexate Therapy on Primary Central Nervous System Lymphoma: A Single Institution Experience
Keishi Makino(Japan)

O-125 PCNSL: A Single-Centre Experience of Unselected Cases Treated with MTX Monotherapy and High-Dose Chemotherapy with Autologous Stem-Cell Transplant
Yoko Nakasu(Japan)

O-126 Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos(USA)

O-127 CD15 Is a Key Player in Non-Small Cell Lung Cancer Brain Metastasis and Is Regulated by Fut-7/4 Enzymes and Cell Cycle
Geoffrey J. Pilkington(UK)

O-128 Beta-Sitosterol Causes a Broad Spectrum Suppression of Melanoma Brain Metastasis
Rolf Bjerkvig(Norway)

O-129 NEO212: A New Drug for Triple Negative Breast Cancer Metastasis to Brain
Thomas C. Chen(USA)

O-130 CpG Methylation Profiling of Meningioma
Kenneth D. Aldape(USA)

O-131 Meningioma Tumor Volume Correlation with MIB-1 Index, Microvascular Density and Patient Outcome
Randy L. Jensen(USA)

O-132 177Lu-DOTATATE/90Y-DOTATOC Peptide Receptor Radionuclide Therapy in Treatment Refractory Progressive Meningioma
Joerg C. Tonn(Germany)

O-133 The Somatic Landscape of Schwannoma
Sameer Agnihotri(USA)

O-134 Web-Based Efforts to Study Brain Tumors
Elizabeth B. Claus(USA)

10:54~11:12 **Session 14 Surgery, etc.**

Moderator: **Takamitsu Fujimaki (Japan)**

O-135 The Use of Clinical fMRI in Brain Tumor Surgery Planning
Joseph Megyesi(Canada)

O-136 A Prospective Phase II Clinical Trial of 5-Aminolevulinic Acid to Correlate Intraoperative Flourescence Intensity with Histologic Cellularity
Mitchel S. Berger(USA)

O-137 Early Postoperative Expansion of Parenchymal High-Intensity Areas on T₂-Weighted Imaging and Delayed Cerebral Edema After Carmustine Wafer Implantation for High-Grade Glioma
Eiichi Ishikawa(Japan)

O-138 Safety and Efficacy of BCNU Wafers in the Treatment of Japanese Glioma Patients
Yukihiko Sonoda(Japan)

O-139 Efficacy and Adverse Events of Carmustine Wafers Implantation for the Treatments of High Grade Gliomas in a Single Institute
Toshihiro Kumabe(Japan)

O-140 Initial Experience in a Pilot Study of Blood-Brain Barrier Opening for Chemo-Drug Delivery to Brain Tumors by MR-Guided Focused Ultrasound
James Perry(Canada)

11:15~11:39 **Session 15 Other Clinical Issues**

Moderator: Joachim Steinbach (Germany)

O-141 A Complete National-Based Registration of Primary Tumours Support a Fair and Optimal Management of High International Standard
Roger Henriksson(Sweden)

O-142 Sex-Specific Transcriptional Networks Underlie Sex Differences in GBM Biology
Joshua B. Rubin(USA)

O-143 Health-Related Quality of Life in Long-Term Survivors with Grade II Gliomas: The Contribution of Disease Recurrence and Karnofsky Performance Status
Yoshiko Okita(Japan)

O-144 Clinicopathological Study of Long Survivors of Glioblastoma (GBM) – Multiinstitutional Retrospective Survey
Takamitsu Fujimaki(Japan)

O-145 Favorable Outcome of 1p/19q Co-Deleted Anaplastic Oligodendroglial Tumors Treated with PAV Chemotherapy Without Radiation Therapy
Tomoo Matsutani(Japan)

O-146 Phase I/II Study of a Combination of Temozolomide with ACNU for Patients with Recurrent Malignant Gliomas
Tomokazu Aoki(Japan)

O-147 The Importance of Early Diagnosis and Treatment in Glioblastomas
Yoshitaka Narita(Japan)

O-148 Molecular Subgroup Analysis of EORTC 26082 (Phase 2) Tensirolimus and RT Versus TMZ/RT->TMZ in Patients with MGMT Unmethylated Newly Diagnosed GBM
Monika E. Hegi(Switzerland)

11:45~12:45 **Lunchtime Seminar 3** (Sponsor: Novocure Ltd.)

Moderator: Ryo Nishikawa (Japan)

LS-3 Tumor Treating Fields – How to Integrate This Novel Modality in Clinical Trials for Glioblastoma
Roger Stupp(Switzerland)

12:50~ **Closing remarks**

Conference Chair: Ryo Nishikawa (Japan) , Next Conference Chair: Rolf Bjerkvig (Norway)
